Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

537 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Radiation treatment of benign tumors in NF2-related-schwannomatosis: A national study of 266 irradiated patients showing a significant increase in malignancy/malignant progression.
Evans DG, Halliday D, Obholzer R, Afridi S, Forde C, Rutherford SA, Hammerbeck-Ward C, Lloyd SK, Freeman SM, Pathmanaban ON, Thomas OM, Laitt RD, Stivaros S, Kilday JP, Vassallo G, McBain C, Lavin T, Paterson C, Whitfield G, McCabe MG, Axon PR, Halliday J, Mackeith S, Parry A; English Specialist NF2 Research Group; Harkness EF, Buttimore J, King AT. Evans DG, et al. Among authors: parry a. Neurooncol Adv. 2023 Mar 11;5(1):vdad025. doi: 10.1093/noajnl/vdad025. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37051330 Free PMC article.
Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients.
Hexter A, Jones A, Joe H, Heap L, Smith MJ, Wallace AJ, Halliday D, Parry A, Taylor A, Raymond L, Shaw A, Afridi S, Obholzer R, Axon P, King AT; English Specialist NF2 Research Group; Friedman JM, Evans DG. Hexter A, et al. Among authors: parry a. J Med Genet. 2015 Oct;52(10):699-705. doi: 10.1136/jmedgenet-2015-103290. Epub 2015 Aug 14. J Med Genet. 2015. PMID: 26275417
Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort.
Morris KA, Golding JF, Blesing C, Evans DG, Ferner RE, Foweraker K, Halliday D, Jena R, McBain C, McCabe MG, Swampillai A, Warner N, Wilson S, Parry A, Afridi SK; UK NF2 research group. Morris KA, et al. Among authors: parry a. J Neurooncol. 2017 Jan;131(1):117-124. doi: 10.1007/s11060-016-2276-9. Epub 2016 Oct 28. J Neurooncol. 2017. PMID: 27796735
Malignant Peripheral Nerve Sheath Tumors are not a Feature of Neurofibromatosis Type 2 in the Unirradiated Patient.
King AT, Rutherford SA, Hammerbeck-Ward C, Lloyd SK, Freeman SR, Pathmanaban ON, Kellett M, Obholzer R, Afridi S, Axon P, Halliday D, Parry A, Thomas OM, Laitt RD, McCabe MG, Stivaros S, Erridge S, Evans DG; English Specialist NF2 research group. King AT, et al. Among authors: parry a. Neurosurgery. 2018 Jul 1;83(1):38-42. doi: 10.1093/neuros/nyx368. Neurosurgery. 2018. PMID: 28973692
Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation.
Morris KA, Golding JF, Axon PR, Afridi S, Blesing C, Ferner RE, Halliday D, Jena R, Pretorius PM; UK NF2 Research group; Evans DG, McCabe MG, Parry A. Morris KA, et al. Among authors: parry a. Neurooncol Pract. 2016 Dec;3(4):281-289. doi: 10.1093/nop/npv065. Epub 2016 Jan 7. Neurooncol Pract. 2016. PMID: 29692918 Free PMC article.
Identifying the deficiencies of current diagnostic criteria for neurofibromatosis 2 using databases of 2777 individuals with molecular testing.
Evans DG, King AT, Bowers NL, Tobi S, Wallace AJ, Perry M, Anup R, Lloyd SKL, Rutherford SA, Hammerbeck-Ward C, Pathmanaban ON, Stapleton E, Freeman SR, Kellett M, Halliday D, Parry A, Gair JJ, Axon P, Laitt R, Thomas O, Afridi S, Ferner RE, Harkness EF, Smith MJ; English Specialist NF2 Research Group. Evans DG, et al. Among authors: parry a. Genet Med. 2019 Jul;21(7):1525-1533. doi: 10.1038/s41436-018-0384-y. Epub 2018 Dec 7. Genet Med. 2019. PMID: 30523344 Free article.
Incidence of mosaicism in 1055 de novo NF2 cases: much higher than previous estimates with high utility of next-generation sequencing.
Evans DG, Hartley CL, Smith PT, King AT, Bowers NL, Tobi S, Wallace AJ, Perry M, Anup R, Lloyd SKW, Rutherford SA, Hammerbeck-Ward C, Pathmanaban ON, Stapleton E, Freeman SR, Kellett M, Halliday D, Parry A, Gair JJ, Axon P, Laitt R, Thomas O, Afridi SK, Obholzer R; English Specialist NF research group; Duff C, Stivaros SM, Vassallo G, Harkness EF, Smith MJ. Evans DG, et al. Among authors: parry a. Genet Med. 2020 Jan;22(1):53-59. doi: 10.1038/s41436-019-0598-7. Epub 2019 Jul 5. Genet Med. 2020. PMID: 31273341 Free article.
Neurofibromatosis type 2 and related disorders.
Halliday D, Parry A, Evans DG. Halliday D, et al. Among authors: parry a. Curr Opin Oncol. 2019 Nov;31(6):562-567. doi: 10.1097/CCO.0000000000000579. Curr Opin Oncol. 2019. PMID: 31425178 Review.
English consensus protocol evaluating candidacy for auditory brainstem and cochlear implantation in neurofibromatosis type 2.
Tysome JR, Axon PR, Donnelly NP, Evans DG, Ferner RE, O'Connor AF, Freeman SR, Gleeson M, Halliday D, Harris F, Jiang D, Kerr R, King A, Knight RD, Lloyd SK, Macfarlane R, Mannion R, Mawman D, O'Driscoll M, Parry A, Ramsden J, Ramsden R, Rutherford SA, Saeed SR, Thomas N, Vanat ZH. Tysome JR, et al. Among authors: parry a. Otol Neurotol. 2013 Dec;34(9):1743-7. doi: 10.1097/MAO.0b013e3182a1a8b4. Otol Neurotol. 2013. PMID: 24136318
Genetic Severity Score predicts clinical phenotype in NF2.
Halliday D, Emmanouil B, Pretorius P, MacKeith S, Painter S, Tomkins H, Evans DG, Parry A. Halliday D, et al. Among authors: parry a. J Med Genet. 2017 Oct;54(10):657-664. doi: 10.1136/jmedgenet-2017-104519. Epub 2017 Aug 28. J Med Genet. 2017. PMID: 28848060 Free PMC article.
537 results